Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BXQ-350 / Bexion
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma	Active, not recruiting	1/2	195	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services	Metastatic Colorectal Carcinoma, Neuropathy	04/26	04/29
KONQUER, NCT04771897: A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)	Terminated	1	10	US	BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, SapC-DOPS, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant	10/24	10/24
ETERNITI, NCT04404569: Continued Treatment for Participants Enrolled in Studies of BXQ-350	Terminated	1	5	US	BXQ-350, SapC-DOPS	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Neoplasms	09/24	09/24
RETRO, NCT05291286: BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients	Completed	1	21	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
BXQ-350 / Bexion
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma	Active, not recruiting	1/2	195	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services	Metastatic Colorectal Carcinoma, Neuropathy	04/26	04/29
KONQUER, NCT04771897: A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)	Terminated	1	10	US	BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, SapC-DOPS, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant	10/24	10/24
ETERNITI, NCT04404569: Continued Treatment for Participants Enrolled in Studies of BXQ-350	Terminated	1	5	US	BXQ-350, SapC-DOPS	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Neoplasms	09/24	09/24
RETRO, NCT05291286: BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients	Completed	1	21	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., CTI Clinical Trial and Consulting Services	Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy	12/24	12/24